Chapter 1. Role of selected transcription factors in pancreatic and colorectal cancer growth and metastasis.- Chapter 2. Adiponectin in gastrointestinal malignancies.- Chapter 3. Small molecule-targeted therapies for GI cancers: success and failures.- Chapter 4. Epigenetic biomarkers for the detection of Gastrointestinal Cancers.- Chapter 5. CD151: A Lateral organizer and modulator of Tumor microenvironment in gastrointestinal cancers.- Chapter 6. Targeting Pathways in GI Malignancies.- Chapter 7. Identification of Potential Key Genes Involved In Progression of Gastric Cancer Using Bioinformatics Analysis.- Chapter 8. Recent Development in the biomarkers for the gastric cancer.- Chapter 9. Gastric Cancer and it’s remedy.- Chapter 10. An intergenic variant rs4779584 between SCG5 and GREM1 contributes to the increased risk of colorectal cancer: A meta-analysis.- Chapter 11. Phytochemicals plus nanomaterial’s on colorectal cancer.- Chapter 12. Pancreatic Ductal Adenocarcinoma and Type 2 Diabetes Mellitus: Distant Relatives or the Close Ones?.- Chapter 13. Tumor Biomarkers and Diagnosis of Pancreatic Adenocarcinoma.- Chapter 14. Immunotherapy in Gastrointestinal Malignancies.- Chapter 15. The Role of HIF-1α in Hepatocellular Carcinoma.
Dr. Nagaraju GP is a faculty member in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Nagaraju obtained his PhD, in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. Dr. Nagaraju received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 90 research papers in highly reputed International journals and has presented more than 50 abstracts at various national and international conferences. Dr, Nagaraju is author and editor of several published books. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju is an associate member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with many international and national professional agencies.
Dr. Sujatha Peela is a full-time Professor in the Department of Biotechnology, Dr.B.R.Ambedkar University, Srikakulam, Andhra Pradesh, INDIA. Dr. Peela received her Doctorate in Biotechnology from Andhra University, Visakhapatnam, INDIA. Furthermore, she pursued her postdoctoral fellowship from the University of Chicago, USA in the Department of Medicine. She has published 33 research papers in various highly reputed International journals and attended 84 national and international conferences. Dr. Peela has published 4 books at international level. She received many prestigious awards from many government agencies & NGOs. Currently, she is playing critical roles in the administration of the state & central including, Principal, for College of Science, Dean for Research Development & Foreign Relations, Faculty Chairperson, in Dr.B.R. Ambedkar University. She organized 16 national and international conferences at various platforms in the Biotechnology field. She has one patent TEMP/E-1/44893/2018-DEL in India. She has membership with many international and national professional agencies.
This book provides an up-to-date overview of gastrointestinal malignancies, including prevention, early detection, intervention, and life-extending therapeutics. It also assesses various biomarkers used for diagnostics, prognostics and prediction of response to chemoresistance. Further, it discusses the latest trends in the use of small-molecule targeted therapies and immunotherapies as single agents or combination with other treatments. Since resistance to radiation and chemotherapy contribute to the high recurrence and poor survival rates, improving the outcome for GI malignancies is dependent on the introduction of new biomarkers and therapeutic agents.
Lastly, the book systematically investigates novel theranostics approaches using nanotechnology for the detection, diagnosis, and personalized treatment of GI malignancies.